论文部分内容阅读
为了提高对系统性硬皮病及皮肌炎的临床确诊率,通过ENA抗原应用免疫印迹技术检测了19例系统性硬皮病(SS)及28例皮肌炎或多发性肌炎(DM/PM)患者抗Scl70及抗Jo1抗体,并与系统性红斑狼疮(SLE)、混合性结缔组织病(MCTD)共62例及50例健康人作了对照研究。结果表明:70KD(抗Scl70)多肽抗体是系统性硬皮病的特异性标记抗体,阳性率31.6%;55KD(抗Jo1)多肽抗体是皮肌炎的特异性标记抗体,阳性率46.4%。SLE、MCTD及健康人全部阴性,从而有助于对系统性硬皮病及皮肌炎的鉴别诊断
In order to improve the clinical diagnosis of systemic scleroderma and dermatomyositis, 19 cases of systemic scleroderma (SS) and 28 cases of dermatomyositis or polymyositis (DM / PM) patients with anti-Scl70 and anti-Jo 1 antibodies, and with systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD) a total of 62 cases and 50 healthy people were controlled. The results showed that: 70 KD (anti Scl 70) peptide antibody is a specific scleroderma labeled antibody, the positive rate was 31.6%; 55KD (anti-Jo 1) polypeptide antibody is a specific marker of dermatomyositis Antibody, the positive rate of 46.4%. SLE, MCTD and all the negative healthy people, which will help the differential diagnosis of systemic scleroderma and dermatomyositis